FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792938178> ?p ?o ?g. }

• W2792938178 endingPage "232" @default.
• W2792938178 startingPage "223" @default.
• W2792938178 abstract "<b><i>Objective:</i></b> Chemotherapy with irinotecan plus cisplatin has shown promise in chemo-naïve small-cell lung cancer (SCLC) patients. However, irinotecan treatment for relapsed or refractory SCLC has not been adequately evaluated. This phase II study evaluated the appropriate treatment schedule of irinotecan as a single agent. This study was designed to determine the antitumor activity, toxicity, and survival in previously treated SCLC patients. <b><i>Methods:</i></b> Previously treated SCLC patients with at least one platinum-based regimen received irinotecan (100 mg/m²) on days 1 and 8, every 3 weeks, until disease progression. The assessment of the response rate was the primary endpoint. <b><i>Results:</i></b> Thirty patients were enrolled, with an objective response rate of 41.3% (95% confidence interval [CI] 25.5–59.3), and a disease control rate of 69%. Median progression-free and overall survival was 4.1 months (95% CI, 2.2–5.4) and 10.4 months (95% CI, 8.1–14), respectively. The grade 3/4 hematological toxicities were neutropenia (36.7%), thrombocytopenia (3.3%), anemia (13.3%), and febrile neutropenia (6.6%). There were no grade 4 nonhematological toxicities. Frequent grade 3 nonhematological toxicities included diarrhea (10%), anorexia (6.6%), and hyponatremia (6.6%).<i></i> <b><i>Conclusions:</i></b> This phase II study showed a high objective response rate and long survival. Irinotecan monotherapy schedule used was well tolerated, and could be an active treatment option for these patients." @default.
• W2792938178 created "2018-03-29" @default.
• W2792938178 creator A5011713024 @default.
• W2792938178 creator A5016648722 @default.
• W2792938178 creator A5019965858 @default.
• W2792938178 creator A5022023364 @default.
• W2792938178 creator A5023225309 @default.
• W2792938178 creator A5036676180 @default.
• W2792938178 creator A5036941473 @default.
• W2792938178 creator A5041031153 @default.
• W2792938178 creator A5044257058 @default.
• W2792938178 creator A5053184004 @default.
• W2792938178 creator A5062966266 @default.
• W2792938178 creator A5064152732 @default.
• W2792938178 creator A5064453145 @default.
• W2792938178 creator A5070478862 @default.
• W2792938178 creator A5077309139 @default.
• W2792938178 creator A5082038216 @default.
• W2792938178 creator A5087829407 @default.
• W2792938178 date "2018-01-01" @default.
• W2792938178 modified "2023-09-27" @default.
• W2792938178 title "A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer" @default.
• W2792938178 cites W1536538430 @default.
• W2792938178 cites W1573292320 @default.
• W2792938178 cites W1671086 @default.
• W2792938178 cites W1897082568 @default.
• W2792938178 cites W1932169383 @default.
• W2792938178 cites W1942335159 @default.
• W2792938178 cites W1952431753 @default.
• W2792938178 cites W1968626722 @default.
• W2792938178 cites W1976228473 @default.
• W2792938178 cites W1982075384 @default.
• W2792938178 cites W2014622726 @default.
• W2792938178 cites W2063897709 @default.
• W2792938178 cites W2065920118 @default.
• W2792938178 cites W2071351256 @default.
• W2792938178 cites W2078751203 @default.
• W2792938178 cites W2080060706 @default.
• W2792938178 cites W2082203970 @default.
• W2792938178 cites W2089063479 @default.
• W2792938178 cites W2096542078 @default.
• W2792938178 cites W2097597328 @default.
• W2792938178 cites W2103702213 @default.
• W2792938178 cites W2108059938 @default.
• W2792938178 cites W2115465348 @default.
• W2792938178 cites W2120277401 @default.
• W2792938178 cites W2120435735 @default.
• W2792938178 cites W2131664752 @default.
• W2792938178 cites W2133122469 @default.
• W2792938178 cites W2139248078 @default.
• W2792938178 cites W2142055223 @default.
• W2792938178 cites W2146589818 @default.
• W2792938178 cites W2158127925 @default.
• W2792938178 cites W2159921901 @default.
• W2792938178 cites W2166206640 @default.
• W2792938178 cites W2166418266 @default.
• W2792938178 cites W2169186295 @default.
• W2792938178 cites W2170260373 @default.
• W2792938178 cites W2230155084 @default.
• W2792938178 cites W2230736893 @default.
• W2792938178 cites W2408997072 @default.
• W2792938178 cites W2418354692 @default.
• W2792938178 cites W2421496331 @default.
• W2792938178 cites W2745840031 @default.
• W2792938178 cites W56918440 @default.
• W2792938178 doi "https://doi.org/10.1159/000486622" @default.
• W2792938178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29444512" @default.
• W2792938178 hasPublicationYear "2018" @default.
• W2792938178 type Work @default.
• W2792938178 sameAs 2792938178 @default.
• W2792938178 citedByCount "27" @default.
• W2792938178 countsByYear W27929381782018 @default.
• W2792938178 countsByYear W27929381782019 @default.
• W2792938178 countsByYear W27929381782020 @default.
• W2792938178 countsByYear W27929381782021 @default.
• W2792938178 countsByYear W27929381782022 @default.
• W2792938178 countsByYear W27929381782023 @default.
• W2792938178 crossrefType "journal-article" @default.
• W2792938178 hasAuthorship W2792938178A5011713024 @default.
• W2792938178 hasAuthorship W2792938178A5016648722 @default.
• W2792938178 hasAuthorship W2792938178A5019965858 @default.
• W2792938178 hasAuthorship W2792938178A5022023364 @default.
• W2792938178 hasAuthorship W2792938178A5023225309 @default.
• W2792938178 hasAuthorship W2792938178A5036676180 @default.
• W2792938178 hasAuthorship W2792938178A5036941473 @default.
• W2792938178 hasAuthorship W2792938178A5041031153 @default.
• W2792938178 hasAuthorship W2792938178A5044257058 @default.
• W2792938178 hasAuthorship W2792938178A5053184004 @default.
• W2792938178 hasAuthorship W2792938178A5062966266 @default.
• W2792938178 hasAuthorship W2792938178A5064152732 @default.
• W2792938178 hasAuthorship W2792938178A5064453145 @default.
• W2792938178 hasAuthorship W2792938178A5070478862 @default.
• W2792938178 hasAuthorship W2792938178A5077309139 @default.
• W2792938178 hasAuthorship W2792938178A5082038216 @default.
• W2792938178 hasAuthorship W2792938178A5087829407 @default.
• W2792938178 hasConcept C121608353 @default.
• W2792938178 hasConcept C126322002 @default.
• W2792938178 hasConcept C2776256026 @default.

• next